Where does Transgene SA rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Transgene SA ranks #11,487 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Transgene SA hold?

Transgene SA holds 27 US utility patents granted between 2015 and 2023, spanning 8 technology areas.

What is Transgene SA's Innovation Score?

Transgene SA has an Innovation Score of 34.2 out of 100 (47th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Transgene SA focus on?

Transgene SA's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 25 patents, ranking #782 of 6,058 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Transgene SA's patent grant rate increasing or decreasing?

Transgene SA's recent grant velocity is -71% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Transgene SA's patents?

Transgene SA's patents average 19.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Transgene SA patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Transgene SA

USPTO PatentsView assignee record - 27 granted patents across 8 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Transgene ranks #11,487 of 49,997 tracked US assignees by granted-patent volume, with 27 patents across 8 technology areas.

#11,487
of 49,997 US assignees by volume: 47th percentile
by Innovation Score (34.2/100): 19.8
avg claims per patent: -71%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11487 · Foreign Corporation #11,487 · 27 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 27 grants
UPPER-Q #11,487/49,997
PHOTO-FINISH TLC Biopharmaceuticals
CPC-NARROW A61P · 8 areas
INNOV-THIN 34.2/100
CLAIMS-RICH 19.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -71% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: TLC Biopharmaceuticals, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Transgene’s 34.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.5 pts (34%) Velocity 0.8 pts (2%) Breadth 10.0 pts (29%) Claim depth 11.9 pts (35%)

Qualcomm Incorporated · highest

85
LDR Medical · near

34
Scholar Rock · near

34
Hill-Rom Services PTE · near

34
Transgene · this assignee

34
OptiNose AS · near

34
3D Lighting… · lowest

7

What this shows Transgene's Innovation Score is 34.2/100 (47th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Transgene?

Each dot is one of Transgene’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Transgene’s own 19.8 claims/patent is ABOVE the 9.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Transgene vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Transgene's grants concentrate

Transgene SA is a focused PatentsView assignee: 8 CPC subclasses with 92.6% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (7 grants) versus a trough of 1 in 2023. By volume, Transgene sits between TLC Biopharmaceuticals, Inc. and Turkiye Sise VE CAM Fabrikalari Anonim Sirketi.

Transgene's three-year grant acceleration

Transgene SA shows 1 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

TLC Biopharmaceut…

27
Tokyo Electric Po…

27
Toyo Aerosol Indu…

27
Toyo Boseki

27
Trinity Internati…

27
Triune IP

27
Trumpf Lasersyste…

27
Turkiye Sise VE C…

27
Transgene ◀

27

What this shows Transgene holds 27 patents at rank #11,471, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Transgene

By rank, the assignees closest to #11,471 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Transgene's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Transgene, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Transgene ranks #782 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (34 here).

Hill-Rom Services PTE. Ltd. 34 OptiNose AS 34 Scholar Rock, Inc. 34 LDR Medical 34

Transgene's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 47th percentile higher than 47% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Transgene SA patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	7	25.9%
2016	5	18.5%
2017	2	7.4%
2018	4	14.8%
2019	3	11.1%
2020	5	18.5%
2023	1	3.7%

Which technologies does Transgene SA patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 25

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 24

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 24

C07K - Peptides 19

C12Y - Enzymes 7

Y02A - Technologies FOR Adaptation TO Climate Change 5

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Transgene SA's patent record in context - here's where to go next.

Transgene SA's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 92.6% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #11,487 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Transgene SA against TLC Biopharmaceuticals, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.